NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 37.7% and is now trading at $17.51. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics Inc (NASDAQ:NTLA) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.24. The company had revenue of $12.92 million for the quarter, compared to analysts' expectations of $21.98 million. Intellia Therapeutics had a negative net margin of 239.98% and a negative return on equity of 40.89%. The firm's quarterly revenue was up 23.8% on a year-over-year basis. During the same period last year, the company earned ($0.49) EPS. View Intellia Therapeutics' earnings history.

7 equities research analysts have issued 1 year price targets for Intellia Therapeutics' stock. Their forecasts range from $16.00 to $57.50. On average, they anticipate Intellia Therapeutics' stock price to reach $26.42 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

News articles about NTLA stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intellia Therapeutics earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIntellia Therapeutics.

Some companies that are related to Intellia Therapeutics include Myriad Genetics (MYGN), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Arca Biopharma (ABIO), Trinity Biotech (TRIB), GeneNews (GNWSF) and Akers Biosciences (AKER). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (13.81%), Sumitomo Mitsui Trust Holdings Inc. (14.51%), Nikko Asset Management Americas Inc. (13.81%), BlackRock Inc. (7.38%), State Street Corp (3.36%) and Morgan Stanley (1.26%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Jean Francois Formela and Jose E Rivera. View institutional ownership trends for Intellia Therapeutics.

NTLA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Intellia Therapeutics.

NTLA stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Aigen Investment Management LP, State Street Corp, Los Angeles Capital Management & Equity Research Inc., and Two Sigma Advisers LP. View insider buying and selling activity for Intellia Therapeutics.

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTLA stock can currently be purchased for approximately $17.51.

Intellia Therapeutics has a market capitalization of $899.66 million and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]